nct_id,title,overall_status,study_type,phases,conditions,lead_sponsor,group_id,group_title,num_at_risk,total_serious_ae,total_other_ae,interventions,arm_label,arm_inferred_intervention,intervention_class,sae_rate,other_ae_rate
NCT01392326,"Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)",COMPLETED,INTERVENTIONAL,PHASE3,Psoriatic Arthritis,Novartis Pharmaceuticals,EG000,Any AIN457 75 mg,292,63,714,Placebo Comparator; Secukinumab (150 mg); Secukinumab (75 mg),Any AIN457 75 mg,,other,0.215753,2.445205
NCT01392326,"Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)",COMPLETED,INTERVENTIONAL,PHASE3,Psoriatic Arthritis,Novartis Pharmaceuticals,EG001,Any AIN457 150 mg,295,81,745,Placebo Comparator; Secukinumab (150 mg); Secukinumab (75 mg),Any AIN457 150 mg,,other,0.274576,2.525424
NCT01392326,"Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)",COMPLETED,INTERVENTIONAL,PHASE3,Psoriatic Arthritis,Novartis Pharmaceuticals,EG002,Placebo,202,12,166,Placebo Comparator; Secukinumab (150 mg); Secukinumab (75 mg),Placebo,,other,0.059406,0.821782
NCT02690948,Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer,COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2",Skin Basal Cell Carcinoma,Anne Chang,EG000,Pembrolizumab Monotherapy,9,5,72,Pembrolizumab; Vismodegib,Pembrolizumab Monotherapy,Pembrolizumab,mab,0.555556,8.000000
NCT02690948,Pembrolizumab With or Without Vismodegib in Treating Metastatic or Unresectable Basal Cell Skin Cancer,COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2",Skin Basal Cell Carcinoma,Anne Chang,EG001,Pembrolizumab Plus Vismodegib Combination Therapy,7,3,39,Pembrolizumab; Vismodegib,Pembrolizumab Plus Vismodegib Combination Therapy,Pembrolizumab,mab,0.428571,5.571429
NCT00582166,Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance,TERMINATED,INTERVENTIONAL,PHASE2,Non-Hodgkin's Lymphoma,"University of Wisconsin, Madison",EG000,Zevalin With Rituximab Maintenance,16,7,151,Ibritumomab Tiuxetan (Zevalin) + Rituximab,Zevalin With Rituximab Maintenance,,other,0.437500,9.437500
NCT00091026,Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer,COMPLETED,INTERVENTIONAL,PHASE2,"Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer",National Cancer Institute (NCI),EG000,"Arm I (Cetuximab, Gemcitabine Hydrochloride, Bevacizumab)",71,47,84,bevacizumab; cetuximab; erlotinib hydrochloride; gemcitabine hydrochloride,"Arm I (Cetuximab, Gemcitabine Hydrochloride, Bevacizumab)",gemcitabine hydrochloride,other,0.661972,1.183099
NCT00091026,Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer,COMPLETED,INTERVENTIONAL,PHASE2,"Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer",National Cancer Institute (NCI),EG001,"Arm II (Gemcitabine Hydrochloride, Bevacizumab, Erlotinib)",68,28,104,bevacizumab; cetuximab; erlotinib hydrochloride; gemcitabine hydrochloride,"Arm II (Gemcitabine Hydrochloride, Bevacizumab, Erlotinib)",gemcitabine hydrochloride,other,0.411765,1.529412
NCT00820248,Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer,COMPLETED,INTERVENTIONAL,PHASE3,Head and Neck Cancer,NCIC Clinical Trials Group,EG000,Cisplatin,156,0,2864,3-dimensional conformal radiation therapy; accelerated radiation therapy; cisplatin; intensity-modulated radiation therapy; panitumumab,Cisplatin,cisplatin,other,0.000000,18.358974
NCT00820248,Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer,COMPLETED,INTERVENTIONAL,PHASE3,Head and Neck Cancer,NCIC Clinical Trials Group,EG001,Panitumumab,159,0,3017,3-dimensional conformal radiation therapy; accelerated radiation therapy; cisplatin; intensity-modulated radiation therapy; panitumumab,Panitumumab,panitumumab,mab,0.000000,18.974843
NCT04560166,Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma,TERMINATED,INTERVENTIONAL,PHASE2,Neuroblastoma Recurrent,Y-mAbs Therapeutics,EG000,Naxitamab and GM-CSF in Combination With Irinotecan and Temozolomide,2,3,34,Naxitamab and GM-CSF in combination with irinotecan and temozolomide,Naxitamab and GM-CSF in Combination With Irinotecan and Temozolomide,Naxitamab and GM-CSF in combination with irinotecan and temozolomide,mab,1.500000,17.000000
NCT00297648,Mucosal Healing Study in Crohn's Disease (CD),COMPLETED,INTERVENTIONAL,PHASE3,Crohn's Disease,UCB Pharma,EG000,CDP870 400 mg,89,60,425,Certolizumab pegol,CDP870 400 mg,,other,0.674157,4.775281
NCT03114657,A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD),TERMINATED,INTERVENTIONAL,PHASE3,Alzheimer's Disease,Hoffmann-La Roche,EG000,Placebo,398,60,82,Crenezumab; Placebo,Placebo,Placebo,other,0.150754,0.206030
NCT03114657,A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD),TERMINATED,INTERVENTIONAL,PHASE3,Alzheimer's Disease,Hoffmann-La Roche,EG001,Crenezumab,404,42,95,Crenezumab; Placebo,Crenezumab,Crenezumab,mab,0.103960,0.235149
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG000,Part 1: GSK3174998 0.003 mg/kg,1,2,4,GSK3174998; Pembrolizumab,Part 1: GSK3174998 0.003 mg/kg,GSK3174998,other,2.000000,4.000000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG001,Part 1: GSK3174998 0.01 mg/kg,1,0,10,GSK3174998; Pembrolizumab,Part 1: GSK3174998 0.01 mg/kg,GSK3174998,other,0.000000,10.000000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG002,Part 1: GSK3174998 0.03 mg/kg,8,4,40,GSK3174998; Pembrolizumab,Part 1: GSK3174998 0.03 mg/kg,GSK3174998,other,0.500000,5.000000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG003,Part 1: GSK3174998 0.1 mg/kg,10,8,71,GSK3174998; Pembrolizumab,Part 1: GSK3174998 0.1 mg/kg,GSK3174998,other,0.800000,7.100000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG004,Part 1: GSK3174998 0.3 mg/kg,10,2,49,GSK3174998; Pembrolizumab,Part 1: GSK3174998 0.3 mg/kg,GSK3174998,other,0.200000,4.900000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG005,Part 1: GSK3174998 1.0 mg/kg,4,2,20,GSK3174998; Pembrolizumab,Part 1: GSK3174998 1.0 mg/kg,GSK3174998,other,0.500000,5.000000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG006,Part 1: GSK3174998 3.0 mg/kg,7,5,48,GSK3174998; Pembrolizumab,Part 1: GSK3174998 3.0 mg/kg,GSK3174998,other,0.714286,6.857143
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG007,Part 1: GSK3174998 10.0 mg/kg,4,2,30,GSK3174998; Pembrolizumab,Part 1: GSK3174998 10.0 mg/kg,GSK3174998,other,0.500000,7.500000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG008,Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg,5,1,20,GSK3174998; Pembrolizumab,Part 2A: GSK3174998 0.003 mg/kg + Pembrolizumab 200 mg,Pembrolizumab,mab,0.200000,4.000000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG009,Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg,5,2,45,GSK3174998; Pembrolizumab,Part 2A: GSK3174998 0.01 mg/kg + Pembrolizumab 200 mg,Pembrolizumab,mab,0.400000,9.000000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG010,Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg,10,9,48,GSK3174998; Pembrolizumab,Part 2A: GSK3174998 0.03 mg/kg + Pembrolizumab 200 mg,Pembrolizumab,mab,0.900000,4.800000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG011,Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg,12,7,93,GSK3174998; Pembrolizumab,Part 2A: GSK3174998 0.1 mg/kg + Pembrolizumab 200 mg,Pembrolizumab,mab,0.583333,7.750000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG012,Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg,14,10,96,GSK3174998; Pembrolizumab,Part 2A: GSK3174998 0.3 mg/kg + Pembrolizumab 200 mg,Pembrolizumab,mab,0.714286,6.857143
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG013,Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg,12,5,97,GSK3174998; Pembrolizumab,Part 2A: GSK3174998 1.0 mg/kg + Pembrolizumab 200 mg,Pembrolizumab,mab,0.416667,8.083333
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG014,Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg,12,2,72,GSK3174998; Pembrolizumab,Part 2A: GSK3174998 3.0 mg/kg + Pembrolizumab 200 mg,Pembrolizumab,mab,0.166667,6.000000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG015,Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg,4,3,16,GSK3174998; Pembrolizumab,Part 2A: GSK3174998 10.0 mg/kg + Pembrolizumab 200 mg,Pembrolizumab,mab,0.750000,4.000000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG016,Part 2B: Melanoma Cohort,9,1,39,GSK3174998; Pembrolizumab,Part 2B: Melanoma Cohort,,other,0.111111,4.333333
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG017,Part 2B: Soft Tissue Sarcoma Cohort,8,2,53,GSK3174998; Pembrolizumab,Part 2B: Soft Tissue Sarcoma Cohort,,other,0.250000,6.625000
NCT02528357,GSK3174998 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors (ENGAGE-1),COMPLETED,INTERVENTIONAL,PHASE1,Neoplasms,GlaxoSmithKline,EG018,Part 2B: NSCLC Cohort,5,1,10,GSK3174998; Pembrolizumab,Part 2B: NSCLC Cohort,,other,0.200000,2.000000
NCT04458857,A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age,COMPLETED,INTERVENTIONAL,PHASE3,Migraine,"Teva Branded Pharmaceutical Products R&D, Inc.",EG000,Placebo,112,3,35,Fremanezumab; Placebo,Placebo,Placebo,other,0.026786,0.312500
NCT04458857,A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age,COMPLETED,INTERVENTIONAL,PHASE3,Migraine,"Teva Branded Pharmaceutical Products R&D, Inc.",EG001,Fremanezumab Dose A,36,1,13,Fremanezumab; Placebo,Fremanezumab Dose A,Fremanezumab,mab,0.027778,0.361111
NCT04458857,A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age,COMPLETED,INTERVENTIONAL,PHASE3,Migraine,"Teva Branded Pharmaceutical Products R&D, Inc.",EG002,Fremanezumab Dose B,87,1,44,Fremanezumab; Placebo,Fremanezumab Dose B,Fremanezumab,mab,0.011494,0.505747
NCT01107457,A Study in Participants With Moderate to Severe Psoriasis,COMPLETED,INTERVENTIONAL,PHASE2,Psoriasis,Eli Lilly and Company,EG000,Placebo,27,1,18,Ixekizumab; Placebo,Placebo,Placebo,other,0.037037,0.666667
NCT01107457,A Study in Participants With Moderate to Severe Psoriasis,COMPLETED,INTERVENTIONAL,PHASE2,Psoriasis,Eli Lilly and Company,EG001,10 mg Ixekizumab,28,1,20,Ixekizumab; Placebo,10 mg Ixekizumab,Ixekizumab,mab,0.035714,0.714286
NCT01107457,A Study in Participants With Moderate to Severe Psoriasis,COMPLETED,INTERVENTIONAL,PHASE2,Psoriasis,Eli Lilly and Company,EG002,25 mg Ixekizumab,30,1,18,Ixekizumab; Placebo,25 mg Ixekizumab,Ixekizumab,mab,0.033333,0.600000
NCT01107457,A Study in Participants With Moderate to Severe Psoriasis,COMPLETED,INTERVENTIONAL,PHASE2,Psoriasis,Eli Lilly and Company,EG003,75 mg Ixekizumab,29,0,21,Ixekizumab; Placebo,75 mg Ixekizumab,Ixekizumab,mab,0.000000,0.724138
NCT01107457,A Study in Participants With Moderate to Severe Psoriasis,COMPLETED,INTERVENTIONAL,PHASE2,Psoriasis,Eli Lilly and Company,EG004,150 mg Ixekizumab,28,0,17,Ixekizumab; Placebo,150 mg Ixekizumab,Ixekizumab,mab,0.000000,0.607143
NCT01107457,A Study in Participants With Moderate to Severe Psoriasis,COMPLETED,INTERVENTIONAL,PHASE2,Psoriasis,Eli Lilly and Company,EG005,Treatment Durability,74,1,12,Ixekizumab; Placebo,Treatment Durability,,other,0.013514,0.162162
NCT01107457,A Study in Participants With Moderate to Severe Psoriasis,COMPLETED,INTERVENTIONAL,PHASE2,Psoriasis,Eli Lilly and Company,EG006,120 mg and 80 mg Total Ixekizumab,120,37,195,Ixekizumab; Placebo,120 mg and 80 mg Total Ixekizumab,Ixekizumab,mab,0.308333,1.625000
NCT01107457,A Study in Participants With Moderate to Severe Psoriasis,COMPLETED,INTERVENTIONAL,PHASE2,Psoriasis,Eli Lilly and Company,EG007,Post Treatment Safety Visits,6,0,1,Ixekizumab; Placebo,Post Treatment Safety Visits,,other,0.000000,0.166667
NCT00583557,A Continuation Trial for Subjects With Rheumatoid Arthritis That Have Completed Protocol LBRA01,TERMINATED,INTERVENTIONAL,PHASE2,Rheumatoid Arthritis,Human Genome Sciences Inc.,EG000,Belimumab 10 mg/kg,153,112,837,belimumab,Belimumab 10 mg/kg,belimumab,mab,0.732026,5.470588
NCT00788957,Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC),COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer, Metastatic Colorectal Cancer, Rectal Cancer","NantBioScience, Inc.",EG000,Part 1: Panitumumab + Rilotumumab,11,7,174,Ganitumab; Panitumumab; Placebo; Rilotumumab,Part 1: Panitumumab + Rilotumumab,Panitumumab,mab,0.636364,15.818182
NCT00788957,Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC),COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer, Metastatic Colorectal Cancer, Rectal Cancer","NantBioScience, Inc.",EG001,Part 2: Panitumumab Alone,48,17,259,Ganitumab; Panitumumab; Placebo; Rilotumumab,Part 2: Panitumumab Alone,Panitumumab,mab,0.354167,5.395833
NCT00788957,Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC),COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer, Metastatic Colorectal Cancer, Rectal Cancer","NantBioScience, Inc.",EG002,Part 2: Panitumumab + Rilotumumab,48,20,271,Ganitumab; Panitumumab; Placebo; Rilotumumab,Part 2: Panitumumab + Rilotumumab,Panitumumab,mab,0.416667,5.645833
NCT00788957,Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC),COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer, Metastatic Colorectal Cancer, Rectal Cancer","NantBioScience, Inc.",EG003,Part 2: Panitumumab + Ganitumab,46,14,262,Ganitumab; Panitumumab; Placebo; Rilotumumab,Part 2: Panitumumab + Ganitumab,Panitumumab,mab,0.304348,5.695652
NCT00788957,Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC),COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer, Metastatic Colorectal Cancer, Rectal Cancer","NantBioScience, Inc.",EG004,Part 3: Rilotumumab,13,8,45,Ganitumab; Panitumumab; Placebo; Rilotumumab,Part 3: Rilotumumab,Rilotumumab,mab,0.615385,3.461538
NCT00788957,Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC),COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Colon Cancer, Colorectal Cancer, Gastrointestinal Cancer, Metastatic Colorectal Cancer, Rectal Cancer","NantBioScience, Inc.",EG005,Part 3: Ganitumab,11,4,65,Ganitumab; Panitumumab; Placebo; Rilotumumab,Part 3: Ganitumab,Ganitumab,mab,0.363636,5.909091
NCT02456857,"Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative",COMPLETED,INTERVENTIONAL,PHASE2,"Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma",M.D. Anderson Cancer Center,EG000,Liposomal Doxorubicin + Bevacizumab + Everolimus,17,6,26,Bevacizumab; Everolimus; Laboratory Biomarker Analysis; Pegylated Liposomal Doxorubicin Hydrochloride,Liposomal Doxorubicin + Bevacizumab + Everolimus,Bevacizumab,mab,0.352941,1.529412
NCT00668148,"A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma",COMPLETED,INTERVENTIONAL,PHASE2,"Ewing's Sarcoma /Peripheral Neuroectodermal Tumor (PNET), Rhabdomyosarcoma, Leiomyosarcoma, Adipocytic Sarcoma, Synovial Sarcoma",Eli Lilly and Company,EG000,Entire Study Population,111,90,371,IMC-A12 (cixutumumab),Entire Study Population,,other,0.810811,3.342342
NCT01648348,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm",National Cancer Institute (NCI),EG000,"Phase I: Bev + TRC105 (Dose 0, Cohort A)",4,8,22,Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Bevacizumab; Laboratory Biomarker Analysis; Pharmacological Study; Quality-of-Life Assessment,"Phase I: Bev + TRC105 (Dose 0, Cohort A)",,other,2.000000,5.500000
NCT01648348,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm",National Cancer Institute (NCI),EG001,"Phase I: Bev + TRC105 (Dose 1, Cohort A)",3,0,25,Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Bevacizumab; Laboratory Biomarker Analysis; Pharmacological Study; Quality-of-Life Assessment,"Phase I: Bev + TRC105 (Dose 1, Cohort A)",,other,0.000000,8.333333
NCT01648348,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm",National Cancer Institute (NCI),EG002,"Phase I: Bev + TRC105 (Dose 2, Cohort A)",4,3,40,Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Bevacizumab; Laboratory Biomarker Analysis; Pharmacological Study; Quality-of-Life Assessment,"Phase I: Bev + TRC105 (Dose 2, Cohort A)",,other,0.750000,10.000000
NCT01648348,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm",National Cancer Institute (NCI),EG003,"Phase I: Bev + TRC105 (Dose 2, Cohort B)",3,4,25,Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Bevacizumab; Laboratory Biomarker Analysis; Pharmacological Study; Quality-of-Life Assessment,"Phase I: Bev + TRC105 (Dose 2, Cohort B)",,other,1.333333,8.333333
NCT01648348,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm",National Cancer Institute (NCI),EG004,Phase II: Bev + TRC105 (Arm I),49,46,465,Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Bevacizumab; Laboratory Biomarker Analysis; Pharmacological Study; Quality-of-Life Assessment,Phase II: Bev + TRC105 (Arm I),,other,0.938776,9.489796
NCT01648348,Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme,COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Recurrent Adult Brain Neoplasm",National Cancer Institute (NCI),EG005,Phase II: Bev Alone (Arm II),43,13,277,Anti-Endoglin Chimeric Monoclonal Antibody TRC105; Bevacizumab; Laboratory Biomarker Analysis; Pharmacological Study; Quality-of-Life Assessment,Phase II: Bev Alone (Arm II),,other,0.302326,6.441860
NCT00748657,Bevacizumab in Treating Patients With Recurrent Sex Cord-Stromal Tumors of the Ovary,COMPLETED,INTERVENTIONAL,PHASE2,"Malignant Ovarian Epithelial Tumor, Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Sex Cord-Stromal Tumor, Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types, Ovarian Steroid Cell Tumor",National Cancer Institute (NCI),EG000,Bevacizumab,36,20,593,Bevacizumab; Laboratory Biomarker Analysis,Bevacizumab,Bevacizumab,mab,0.555556,16.472222
NCT00170157,Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer,COMPLETED,INTERVENTIONAL,PHASE2,"Prostate Adenocarcinoma, Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage III Prostate Cancer, Stage IV Prostate Cancer",Mayo Clinic,EG000,Entire Study Population,110,24,826,Bicalutamide; Flutamide; Goserelin Acetate; Ipilimumab; Leuprolide Acetate; Pharmacological Study,Entire Study Population,,other,0.218182,7.509091
NCT00618657,"Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",COMPLETED,INTERVENTIONAL,PHASE2,"Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer","University of California, Irvine",EG000,Arm I (HER-2 Positive),42,4,38,Carboplatin; bevacizumab; magnetic resonance imaging; paclitaxel albumin-stabilized nanoparticle formulation; therapeutic conventional surgery; trastuzumab,Arm I (HER-2 Positive),,other,0.095238,0.904762
NCT00618657,"Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",COMPLETED,INTERVENTIONAL,PHASE2,"Breast Cancer, HER2-negative Breast Cancer, HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer","University of California, Irvine",EG001,Arm II (HER-2 Negative),85,1,90,Carboplatin; bevacizumab; magnetic resonance imaging; paclitaxel albumin-stabilized nanoparticle formulation; therapeutic conventional surgery; trastuzumab,Arm II (HER-2 Negative),,other,0.011765,1.058824
NCT02810457,Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer,COMPLETED,INTERVENTIONAL,PHASE3,"Carcinoma, Non-Small-Cell Lung",Centus Biotherapeutics Limited,EG000,FKB238 / Paclitaxel / Carboplatin,362,118,1360,Avastin (bevacizumab); Carboplatin; FKB238 (bevacizumab); Paclitaxel,FKB238 / Paclitaxel / Carboplatin,Carboplatin,other,0.325967,3.756906
NCT02810457,Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer,COMPLETED,INTERVENTIONAL,PHASE3,"Carcinoma, Non-Small-Cell Lung",Centus Biotherapeutics Limited,EG001,Avastin / Paclitaxel / Carboplatin,366,127,1527,Avastin (bevacizumab); Carboplatin; FKB238 (bevacizumab); Paclitaxel,Avastin / Paclitaxel / Carboplatin,Carboplatin,other,0.346995,4.172131
NCT00183248,Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients,COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Kidney Transplantation, Kidney Disease, Kidney Failure",University of Miami,EG000,DBMCs,4,13,71,Alemtuzumab; Donor bone marrow stem cell infusion; Kidney transplant; Mycophenolate mofetil; Sirolimus; Tacrolimus,DBMCs,,other,3.250000,17.750000
NCT00183248,Using Donor Stem Cells and Alemtuzumab to Prevent Organ Rejection in Kidney Transplant Patients,COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2","Kidney Transplantation, Kidney Disease, Kidney Failure",University of Miami,EG001,Control Group,5,4,51,Alemtuzumab; Donor bone marrow stem cell infusion; Kidney transplant; Mycophenolate mofetil; Sirolimus; Tacrolimus,Control Group,,other,0.800000,10.200000
NCT00663026,Study Evaluating Bapineuzumab In Alzheimer Disease Subjects,COMPLETED,INTERVENTIONAL,PHASE2,Alzheimer Disease,Pfizer,EG000,Placebo,19,1,49,bapineuzumab; placebo,Placebo,placebo,other,0.052632,2.578947
NCT00663026,Study Evaluating Bapineuzumab In Alzheimer Disease Subjects,COMPLETED,INTERVENTIONAL,PHASE2,Alzheimer Disease,Pfizer,EG001,Bapineuzumab 5 mg,29,2,40,bapineuzumab; placebo,Bapineuzumab 5 mg,bapineuzumab,mab,0.068966,1.379310
NCT00663026,Study Evaluating Bapineuzumab In Alzheimer Disease Subjects,COMPLETED,INTERVENTIONAL,PHASE2,Alzheimer Disease,Pfizer,EG002,Bapineuzumab 10 mg,31,6,39,bapineuzumab; placebo,Bapineuzumab 10 mg,bapineuzumab,mab,0.193548,1.258065
NCT04431726,"A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors",ACTIVE_NOT_RECRUITING,INTERVENTIONAL,PHASE3,Severe Hemophilia A,Hoffmann-La Roche,EG000,Emicizumab,55,29,266,Emicizumab,Emicizumab,Emicizumab,mab,0.527273,4.836364
NCT02312557,Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide,ACTIVE_NOT_RECRUITING,INTERVENTIONAL,PHASE2,"Castration-Resistant Prostate Carcinoma, Hormone-Resistant Prostate Cancer, PSA Progression, Recurrent Prostate Carcinoma, Stage IV Prostate Adenocarcinoma Cancer AJCC v8",OHSU Knight Cancer Institute,EG000,Treatment (Pembrolizumab),58,41,328,Enzalutamide; Laboratory Biomarker Analysis; Pembrolizumab,Treatment (Pembrolizumab),Pembrolizumab,mab,0.706897,5.655172
NCT01914757,Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist,COMPLETED,INTERVENTIONAL,PHASE3,Asthma,AstraZeneca,EG000,Benralizumab 30 mg q.4 Weeks,438,58,408,Benralizumab; Placebo,Benralizumab 30 mg q.4 Weeks,Benralizumab,mab,0.132420,0.931507
NCT01914757,Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist,COMPLETED,INTERVENTIONAL,PHASE3,Asthma,AstraZeneca,EG001,Benralizumab 30 mg q.8 Weeks,428,52,382,Benralizumab; Placebo,Benralizumab 30 mg q.8 Weeks,Benralizumab,mab,0.121495,0.892523
NCT01914757,Efficacy and Safety Study of Benralizumab in Adults and Adolescents Inadequately Controlled on Inhaled Corticosteroid Plus Long-acting β2 Agonist,COMPLETED,INTERVENTIONAL,PHASE3,Asthma,AstraZeneca,EG002,Placebo,440,73,461,Benralizumab; Placebo,Placebo,Placebo,other,0.165909,1.047727
NCT02685826,A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma,COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2",Multiple Myeloma,Celgene,EG000,"Cohort A: High Risk, TNE",25,28,224,Dexamethasone; Durvalumab; Lenalidomide,"Cohort A: High Risk, TNE",,other,1.120000,8.960000
NCT02685826,A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma,COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2",Multiple Myeloma,Celgene,EG001,"Cohort B: >=65 Years Old, TNE",10,8,108,Dexamethasone; Durvalumab; Lenalidomide,"Cohort B: >=65 Years Old, TNE",,other,0.800000,10.800000
NCT02685826,A Study of Durvalumab in Combination With Lenalidomide With and Without Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma,COMPLETED,INTERVENTIONAL,"PHASE1, PHASE2",Multiple Myeloma,Celgene,EG002,"Cohort C: High Risk, Post-transplant",21,8,129,Dexamethasone; Durvalumab; Lenalidomide,"Cohort C: High Risk, Post-transplant",,other,0.380952,6.142857
NCT00110357,Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors,COMPLETED,INTERVENTIONAL,PHASE1,"Cancer, Refractory Solid Tumor",Eli Lilly and Company,EG000,01 75 mg/m2 CET + 20 mg/m2 IRI,14,37,291,Cetuximab + Irinotecan,01 75 mg/m2 CET + 20 mg/m2 IRI,,other,2.642857,20.785714
NCT00110357,Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors,COMPLETED,INTERVENTIONAL,PHASE1,"Cancer, Refractory Solid Tumor",Eli Lilly and Company,EG001,02 150 mg/m2 CET + 20 mg/m2 IRI,10,30,111,Cetuximab + Irinotecan,02 150 mg/m2 CET + 20 mg/m2 IRI,,other,3.000000,11.100000
NCT00110357,Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors,COMPLETED,INTERVENTIONAL,PHASE1,"Cancer, Refractory Solid Tumor",Eli Lilly and Company,EG002,03 150 mg/m2 CET + 16 mg/m2 IRI,3,0,47,Cetuximab + Irinotecan,03 150 mg/m2 CET + 16 mg/m2 IRI,,other,0.000000,15.666667
NCT00110357,Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors,COMPLETED,INTERVENTIONAL,PHASE1,"Cancer, Refractory Solid Tumor",Eli Lilly and Company,EG003,04 250 mg/m2 CET + 16 mg/m2 IRI,12,17,190,Cetuximab + Irinotecan,04 250 mg/m2 CET + 16 mg/m2 IRI,,other,1.416667,15.833333
NCT00110357,Study of Erbitux™ (Cetuximab) in Pediatric Patients With Refractory Solid Tumors,COMPLETED,INTERVENTIONAL,PHASE1,"Cancer, Refractory Solid Tumor",Eli Lilly and Company,EG004,05 250 mg/m2 CET + 20 mg/m2 IRI,7,24,86,Cetuximab + Irinotecan,05 250 mg/m2 CET + 20 mg/m2 IRI,,other,3.428571,12.285714
NCT00842257,Panitumumab in Cetuximab Refractory KRAS Wild-Type Colorectal Cancer,COMPLETED,INTERVENTIONAL,PHASE2,Colorectal Cancer,Massachusetts General Hospital,EG000,Panitumumab,20,0,165,panitumumab,Panitumumab,panitumumab,mab,0.000000,8.250000
NCT01107626,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,COMPLETED,INTERVENTIONAL,PHASE3,Lung Cancer,ECOG-ACRIN Cancer Research Group,EG000,"Arm I (Induction Therapy - Carboplatin, Paclitaxel & Bevacizumab)",1477,2042,3727,Bevacizumab; Carboplatin; Paclitaxel; Pemetrexed Disodium Heptahydrate,"Arm I (Induction Therapy - Carboplatin, Paclitaxel & Bevacizumab)",Bevacizumab,mab,1.382532,2.523358
NCT01107626,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,COMPLETED,INTERVENTIONAL,PHASE3,Lung Cancer,ECOG-ACRIN Cancer Research Group,EG001,Arm A (Maintenance Therapy - Bevacizumab),284,129,524,Bevacizumab; Carboplatin; Paclitaxel; Pemetrexed Disodium Heptahydrate,Arm A (Maintenance Therapy - Bevacizumab),Bevacizumab,mab,0.454225,1.845070
NCT01107626,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,COMPLETED,INTERVENTIONAL,PHASE3,Lung Cancer,ECOG-ACRIN Cancer Research Group,EG002,Arm B (Maintenance Therapy - Pemetrexed),289,217,644,Bevacizumab; Carboplatin; Paclitaxel; Pemetrexed Disodium Heptahydrate,Arm B (Maintenance Therapy - Pemetrexed),,other,0.750865,2.228374
NCT01107626,Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer,COMPLETED,INTERVENTIONAL,PHASE3,Lung Cancer,ECOG-ACRIN Cancer Research Group,EG003,Arm C (Maintenance Therapy - Bevacizumab + Pemetrexed),286,349,848,Bevacizumab; Carboplatin; Paclitaxel; Pemetrexed Disodium Heptahydrate,Arm C (Maintenance Therapy - Bevacizumab + Pemetrexed),Bevacizumab,mab,1.220280,2.965035
